Public-private partnerships leading to successes in HIV treatment and prevention

The recent achievements in studies looking at treatment as prevention "were only made possible by the partnership between publicly funded scientists and private drug companies," Ward Cates, president of research at FHI; Salim Abdool Karim, director of the Centre for the AIDS Program of Research in South Africa; and Myron Cohen, director of the UNC Division of Infectious Disease and the UNC Institute for Global Health and Infectious Disease, write in an opinion piece in the Huffington Post.

"More governments and pharmaceutical companies must join together to ensure the availability of antiretroviral therapy for HIV treatment and prevention at the lowest possible cost in all resource-poor countries. … In addition, governments, non-governmental organizations and the pharmaceutical industry need to collaborate to train health workers to provide HIV treatment and prevention at the community level. Strengthening HIV prevention and treatment services, community outreach and literacy programs, and promoting cross-training among those providing prevention and treatment could be jointly funded by public and private resources," they state (6/17).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New insights into the mechanisms of efavirenz-induced neurotoxicity